Mode
Text Size
Log in / Sign up

Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinomaNew Kidney Cancer Rules Change How Doctors Treat Metastasis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note updated consensus on adjuvant therapy, immunotherapy, and belzutifan for renal cell carcinoma in Hong Kong.

This document is a consensus statement and guideline developed by 6 urologists and 8 clinical oncologists in Hong Kong to update management strategies for locally advanced and metastatic renal cell carcinoma. The panel established consensus statements on management that were accepted if at least 80% of panellists selected 'accept completely' or 'accept with some reservation'.

Key updates include asserting the use of adjuvant therapy for locally advanced renal cell carcinoma and immunotherapy-based combination therapy across different types of metastatic renal cell carcinoma compared with previous versions. The guideline also introduces active surveillance as a new area for mRCC patients with a very favourable prognosis and adds definitions and management for oligometastatic or oligoprogressive renal cell carcinoma. A novel therapeutic agent, belzutifan, is included as a new area for metastatic renal cell carcinoma.

The authors acknowledge that several research gaps remain to be addressed. Safety information, including adverse events, serious adverse events, discontinuations, and tolerability, was not reported. This guideline offers practical references for clinicians in Hong Kong and the Asia-Pacific region, though the evidence base relies on expert consensus rather than randomized trials.

Why these new rules matter

Kidney cancer often spreads before it is found. Doctors used to rely on older methods to fight it. Now, science has moved faster than the rules.

Patients feel confused when treatment options change. They worry about side effects and costs. Clear guidelines help reduce this uncertainty.

The shift in treatment plans

Previously, surgery was the main focus for early stages. Drugs came later if the cancer returned. Now, medicine is used sooner to stop growth.

This helps stop the cancer early. It changes how doctors plan the first steps.

Think of your immune system as a security team. New drugs wake up these guards. They learn to spot cancer cells faster.

Some treatments act like a key in a lock. They block signals that tell cancer to grow. This stops the tumor from getting bigger.

What the experts decided

A group of 14 doctors met to discuss this. They reviewed years of research together. They agreed on 42 new points.

The team included urologists and cancer specialists. They voted on five key areas of care. Most rules needed 80% agreement to pass.

Key changes for patients

Some patients might wait before starting treatment. This is called active surveillance. It helps avoid side effects when not needed.

Adjuvant therapy is now standard after surgery. This means taking medicine to prevent return. It is a big step forward for safety.

This doesn’t mean this treatment is available yet.

If you have advanced kidney cancer, ask about these options. Your doctor knows your history best. These rules help guide their choices.

You should not start new drugs on your own. Talk to your care team first. They can explain if you qualify.

Where the science stands now

This group focused on Asia-Pacific care. But the ideas apply worldwide. Research is always growing and changing.

There are still gaps in our knowledge. Some types of kidney cancer need more study. We must wait for more data.

More studies will test these ideas further. Doctors will update rules as new data arrives. Stay informed and keep talking to your care team.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
BackgroundContinuous efforts have been made to optimise treatment approaches for renal cell carcinoma (RCC), including locally advanced (la)RCC and metastatic (m)RCC. To update their joint consensus statements on the management of la/mRCC, the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology convened a series of Delphi meetings.MethodsA panel of six urologists and eight clinical oncologists was formed, addressing five areas: (i) surgical and (neo)adjuvant treatment in laRCC; (ii) first-line management of clear cell mRCC; (iii) second- and later-line treatment of clear cell mRCC; (iv) management of mRCCs with sarcomatoid features or non-clear cell histology; and (v) management of oligometastatic RCC. Consensus statements were drafted based on an extensive literature review and panel discussions. A consensus statement was established only if ≥ 80% of the panellists selected ‘accept completely’ or ‘accept with some reservation’ from a five-point Likert scale through anonymous voting.ResultsA total of 42 consensus statements were accepted. Compared with the previous version, this set of consensus statements asserted the use of adjuvant therapy for laRCC and the use of immunotherapy-based combination therapy across different types of mRCC; multiple new areas were also added, including active surveillance in mRCC patients with very favourable prognosis, a novel therapeutic agent for mRCC (belzutifan), and the definitions and management of oligometastatic/oligoprogressive RCC.ConclusionWhile several research gaps remain to be addressed, this set of consensus statements reflects contemporary approaches for la/mRCC management, offering practical references for clinicians in Hong Kong and the Asia-Pacific region.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.